Aid conditionalities, international Good Manufacturing Practice standards and local production rights: a case study of local production in Nepal by Brhlikova, P et al.
Aid conditionalities, international Good Manufacturing Practice standards
and local production rights: a case study of local production in Nepal.
Brhlikova, P; Harper, I; Subedi, M; Bhattarai, S; Rawal, N; Pollock, AM
 
 
 
 
 
 
 
For additional information about this publication click this link.
http://qmro.qmul.ac.uk/jspui/handle/123456789/7921
 
 
 
Information about this research object was correct at the time of download; we occasionally
make corrections to records, please therefore check the published record when citing. For
more information contact scholarlycommunications@qmul.ac.uk
RESEARCH Open Access
Aid conditionalities, international Good
Manufacturing Practice standards and local
production rights: a case study of local
production in Nepal
Petra Brhlikova1*†, Ian Harper2†, Madhusudan Subedi3, Samita Bhattarai4, Nabin Rawal5 and Allyson M. Pollock1†
Abstract
Background: Local pharmaceutical production has been endorsed by the WHO as a means of addressing health
priorities of developing countries. However, local producers of essential medicines must comply with international
pharmaceutical standards in order to be eligible to compete in donor tenders. These standards determine
production rights for on-patent and off-patent medicines, and guide international procurement of medicines. We
reviewed the literature on the impact of Good Manufacturing Practice (GMP) on local production; a gap analysis
from the literature review indicated a need for further research. Over sixty interviews were conducted with people
involved in the Nepali pharmaceutical production and distribution chain from 2006 to 2009 on the GMP areas of
relevance: regulatory capacity, staffing, funding and training, resourcing of GMP, inspectors’ interpretation of the
rules and compliance.
Results: Although Nepal producers have increased their overall share of the domestic market, only the public
manufacturer, Royal Drugs, focuses on medicines for public health programmes; private producers engage mainly
in brand competition for private markets, not essential medicines. Nepali regulators and producers state that
implementation of GMP standards is hindered by low regulatory capacity, insufficient training of staff in the
industry, financial constraints and lack of investment for upgrading capital. The transition period to mandatory
compliance with WHO GMP rules is lengthy. Less than half of private producers had WHO GMP in 2013. Producers
are not directly affected by international harmonisation of standards as they do not export medicines and the
Nepali regulator does not enforce the WHO standards strictly. Without an international GMP certificate they cannot
tender for donor dependent health programmes.
Conclusions: In Nepal, local private manufacturers focus mainly on brand competition for private consumption not
essential medicines, the government preferentially procures essential medicines from the only public producer
while donor funded programmes rely on international manufacturers compliant with international GMP standards.
We also found evidence of private hospitals bypassing national medicines approvals process.
Policies in support of local pharmaceutical production in developing countries as a source of essential medicines
need to examine carefully how GMP regulations impact on regulators, local industry and production of essential
medicines in practice.
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Introduction
The Global strategy and plan for action on public health,
innovation and intellectual property adopted by the 61st
WHA in 2008 identified local pharmaceutical production
as one of the key building blocks required for needs-based
essential health research and development addressing
health priorities of developing countries [1]. Initiatives
calling for local pharmaceutical production are not new.
Local production has been on the WHO’s agenda since
1978 and in the 1970s and 1980s governments, UN and
other international organisations supported the develop-
ment of local pharmaceutical production in many low-
income countries on the grounds that it would promote
self-sufficiency in the medicine supply; reduce dependency
on imports and improve foreign trade balances; and create
employment opportunities [2–4]. Although questions
were raised about economic feasibility and product quality
[5] many developing countries succeeded in building a vi-
able pharmaceutical industry satisfying more than 70 % of
their national requirements of essential medicines [6, 7]. A
robust evidence base on the positive impact of local pro-
duction on access to medicines is limited and mixed, with
the majority of studies focusing on the affordability of
local products compared to their imported counterparts
[8]. In a recent study, the locally produced essential medi-
cines in Tanzania showed an overall higher availability
across the country over imported products, which were
more likely to be available in urban areas [9].
Post TRIPS, the strategic importance of local produc-
tion was again brought forward as a way to benefit from
public health flexibilities specified in the Doha Declar-
ation [4]. However, the viability of local production de-
pends on several factors including effective regulation,
funding, technology transfer, economies of scale, and pro-
curement policies. The procurement of essential medi-
cines, especially for donor funded programmes, has been
accompanied by a shift from national governments to
international public-private partnerships so that local pro-
ducers must comply with international pharmaceutical
standards if they are to be eligible for tenders.
This paper is particularly concerned with GMP (Good
Manufacturing Practice) which is a requirement for inter-
national procurement of medicines for donor and publicly
funded health programmes. Although compliance with
GMP is a condition of market entry, as well as conferring
production rights for many essential medicines procured
though international donors, there has been little analysis
of the impact of international GMP standards on local
production for public health systems and government use.
This in itself is of concern as the growth in inter-
national pharmaceutical standards and the process of their
harmonisation, specifically through the International Con-
ference on Harmonisation (ICH), has been criticised for
raising standards and compliance costs with insufficient
attention being paid to whether they improve research on
medicines and the safety of end products [10–12]. The
WHO has warned that the standard setting process of the
ICH is dominated by Western governments and their
research-based pharmaceutical industry, describing the
process as exclusive, non-consultative and lacking in local
knowledge [13]. It also noted that the standards are too
high for local production. Closures of small and medium
producers as well as public vaccine producers due to stric-
ter GMP requirements have been observed, for instance,
in India [14].
Despite the WHO’s criticisms and the importance of
the GMP standards for the availability of affordable and
high-quality medicines and viability of local pharmaceut-
ical production it is not clear from the literature to what
extent local production in low- and middle-income
countries has been affected by the international harmon-
isation of the regulations. In this paper we provide a
brief background to GMP reported studies on the im-
pact of GMP on local production before using the case
study of Nepal to explore GMP implementation and en-
forcement from regulators’ and producers’ perspective in
the context of development aid and aid conditionalities.
Background to GMP standards and their international
harmonisation
According to the WHO, GMP “is that part of quality as-
surance which ensures that products are consistently pro-
duced and controlled to the quality standards appropriate
to their intended use and as required by marketing
authorization” [15]. They apply to producers and other
parties involved in labelling and packaging pharmaceutical
products. GMP standards are intended to reduce the risks
in production process including cross-contamination and
mix-ups (e.g. confusions because of false labelling). GMP
guidelines represent minimal standards that are a neces-
sary condition for marketing authorization.
The WHO prepared its first version of GMP in 1967
at the request of the Twentieth World Health Assembly
[15], but these are not legally binding on member states.
The WHO has made clear that the implementation and
enforcement of GMP is a matter for individual states
and their respective drug regulatory bodies which can
specify different sets of requirements.
In 1975 the WHO attempted to implement the rules at
the global level through the Action Program on Essential
Drugs and the Certification Scheme on the Quality of
Pharmaceutical Products Moving in International Com-
merce. In the Certification Scheme, exporting countries
certify domestic pharmaceutical companies as manufac-
turers of drugs authorized for the domestic market and
that their compliance with the WHO GMP is checked on
a regular basis [16].
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Western industry, quite separately established its own
standard setting initiative. The European Free Trade
Association (EFTA) introduced a Pharmaceutical Inspec-
tion Convention (PIC) in 1970 and complemented it
with Pharmaceutical Inspection Co-operation Scheme in
1995 with the aim of developing and harmonising GMP
and inspection standards and to promote cooperation
among participating authorities including exchange of
information and experience. 44 EFTA and non-EFTA
countries are participating in PIC/S [17].
The most recent and prominent harmonisation effort
via the International Conference on Harmonization (ICH)
is led by pharmaceutical regulators and industry represen-
tatives of the EU, Japan, and the US, and accepted by other
developed countries. In 1999, the ICH brought GMPs for
Active Pharmaceutical Ingredients, which apply to produc-
tion of APIs for on-patent and off-patent medicines in
ICH signatory countries and in other countries such as
Australia and Canada. These guidelines were also adopted
by PIC/S in 2001 and, despite the earlier criticism of ICH
by WHO, formed the basis for the 2010 WHO GMP
guidelines for APIs [18]. ICH standards are thus of grow-
ing importance in policing and regulating the global
pharmaceutical industry and none more so than GMP.
Given their global impact it is worth noting several fea-
tures of the ICH harmonisation process for its implica-
tions for market consolidation and developing countries:
i) Industry driven harmonisation of regulation
In 2000, the WHO warned that the ICH represented
interests of drug regulatory authorities and
representatives of pharmaceutical industry of 17
high-income countries; the negotiation processes
excluded nongovernmental organizations, patient and
consumer groups and lacked consultations with
academics and medical practitioners; and “the
additional safety benefits from these rigorous standards
have not yet been demonstrated but the costs incurred
by manufacturers in meeting these requirements are
significant” [13]. The WHO representing developing
countries has only observer status on ICH.
ii) GMP enforcement in developing countries
Regulatory authorities in developing countries have
been under increasing pressure to adjust their
domestic regulatory systems in response to various
international political issues. Whether it be WHO or
ICH or FDA GMP standards, their implementation
and enforcement is not a low cost exercise, as
pharmaceutical companies and governments must
develop capacity to implement and enforce the
regulation. Although most sub-Saharan Africa
countries have a legal basis for medicine registration,
guidelines and assessment procedures, regulatory
authorities have limited economic and human
resources, and the enforcement of regulations is often
discretionary so that many public and most local
manufacturers do not meet WHO standards [19].
The enforcement of GMP standards, however, is not
just a problem for low- and middle-income
countries. Recent safety concerns over medicines and
APIs imported by developed countries illustrated
difficulties of regulatory agencies to monitor
production facilities of foreign suppliers [20].
iii) medicine procurement and aid conditionalities
GMP standards are enforced through government
drug procurement systems at international, national,
and local level and in particular through aid
conditions. International procurement agents
including GDF and UNOPS require compliance with
WHO GMP standards as a necessary condition for
participation in a tender and may impose other
conditions. Donors may also have their own
requirements: the Global Fund requires compliance
with WHO GMP ensured by the WHO
Prequalification Programme and/or compliance with
the US or EU rules [21]; PEPFAR requires US FDA
GMP standards [22].
These conditions may lock out local companies from
their domestic market. For instance, producers in
Tanzania complying with Tanzanian GMP guidelines
have access to government tenders but cannot
participate in more profitable international tenders
requesting international GMP standards [2] and may
be unable to tender for donor contracts within the
country. Ugandan producers argue that the increased
donor funding towards essential medicines combined
with the requirement of WHO-GMP compliance
means that “they are slowly being pushed out of the
local essential medicines market” and some suggest
that this “might be the single biggest threat to the sur-
vival of local pharmaceutical manufacturing” [23].
Another factor that inhibits local producers is size.
Large MNCs argued for the size criterion to be included
as a necessary condition for participation in international
tenders. Their key argument is that small companies are
not reliable in that they will not be able to supply drugs as
promised [24].
Survival of local pharmaceutical production under inter-
national GMP rules ultimately depends on strength of drug
regulation and access to sufficiently large markets. Stricter
rules and related compliance costs need to be associated
with additional safeguards ensuring medicine safety, efficacy
and quality to be accepted by producers and, perhaps more
importantly, in line with the access to affordable high qual-
ity medicines agenda. Trust in regulatory authorities and
processes is a necessary condition for the rules to be ac-
cepted by purchasers of pharmaceuticals [25] thus securing
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demand which in turn provides incentives for producers to
adopt the rules.
Impact of GMP on local production
Our PubMed search identified only three studies on the is-
sues of GMP in relation to local pharmaceutical production
in low- and middle-income countries; these concerned the
production of vaccines [26], antiretrovirals [27], and anti-
malarials [28]. All three studies emphasize the need for
local producers to invest in their production facilities and
comply with GMP. The two public vaccine producers in
Iran found it difficult to keep up with changing GMP re-
quirements and although they satisfy the local needs, the
informants identified the need for WHO prequalification
and insufficient capacity as the key barriers to the export
[26]. Abdo-Rabbo et al. examined the quality of animalar-
ials at various levels of the distribution chain in Yemen and
concluded that the problems with quality were not limited
to a specific level of distribution chain and concerned lo-
cally produced as well as imported medicines [28]. None of
the identified studies assessed the impact of GMP and their
international harmonisation on local production.
A limited search of grey literature to check for additional
studies and projects yielded two reports by MSF/DND
Working Group which were concerned with the impact of
ICH standards on the development and availability of medi-
cines in developing countries [29, 30]. A comparison with
the ICH and WHO GMP requirements concluded that al-
though there were differences between the two sets of stan-
dards, they were ‘often marginal or formal’. The report
further noted that ‘the main difference between ICH and
WHO specifications is the interpretation of data submitted
by applicants and the enforcement by DRAs’ [30].
In addition to regulatory capacity building, institutions
such as UNIDO, WHO (Prequalification Project), and DfID
support specific local pharmaceutical producers of, primar-
ily, antiretrovirals, anti-TB and antimalarials in achieving
WHO prequalification [31–33]. As of April 2015 only three
out of 419 WHO prequalified medicine products were pro-
duced by a low-income country producer (119 HIC, 297
MIC) and none of prequalified APIs were produced in a
low-income country (3 in HICs, 75 in MICs) [34, 35].
Background to pharmaceutical production and regulation
in Nepal
Allopathic medicine in Nepal has a relatively recent his-
tory. The limited supply of medicines to Nepal was
via India, and the British Embassy for the elite (Inter-
view, Kathmandu University, April 2007) until the first
“people’s movement” of 1950. The more systematic de-
velopment of the health sector began with increasing
development aid assistance and the country’s roll over
five year plans. Nepal government started to manufac-
ture its own drugs in government facilities from the
1950s, focusing initially on medicinal plants and herbal
forms and was located under the Ministry of Forests.
The Royal Drugs Laboratory was set up as a pilot pro-
duction site in 1965, and then converted to Royal Drugs
Limited (RDL) in 1972 - the first production unit in
Nepal (Interview, APPON, December 2006). The first
private company, Chemidrug Industries Pvt. Ltd. was
opened in 1971 (Interview, Kathmandu University, April
2007). The drug Act of 1978 resulted in the Department
of Drug Administration (DDA) being set up in 1979
(where it was still part of the Ministry of Forests). Pre-
cursors to the Drug Act included the Black Marketing
and other Social Offences Act, 2032 BS (1975), and the
Drug Abuse Control Act, 2033 BS (1976) (see [36] for a
full list of all the Acts pertaining to health, and their devel-
opment in Nepal). By 1979 there were two Nepalese com-
panies but around 1000 Indian ones; Nepal was an
extension of the Indian market. It was not till after the late
1980s, however, that the nascent Nepalese industry started
to mushroom. Relocated to a part of the Ministry of
Health and Population, the DDA has overseen this growth
of the Nepal pharmaceutical industry to its size of 58 reg-
istered companies in July 2014 (personal communication),
and been responsible for the regulation of the industry.
Nepali pharmaceutical companies focus on the sec-
ondary and tertiary production (formulation and pack-
aging) and supply medicines only to the local market.
They had a 25-27 % share of the Nepali pharmaceutical
market in 2004 while the import was dominated by In-
dian pharmaceutical producers (170 Indian companies
out of nearly 250 importers) [37]. In interviews, Nepali
producers talked of the 30:70 split in the market be-
tween Nepali and Indian products, and their aims of
reversing this percentage. For 2006–2009 the share of
local manufacture increased to 40 %; with domestic pro-
ducers mainly catering to rural areas, where they have
about 80 % of the market, and having about 20 % of the
urban market [38].
In Nepal, although there is local production of some
essential medicines, the majority are imported. Of the
537 products in various strengths and dosage forms
listed on the 2011 National List of Essential Medicines,
Nepali companies were producing less than one third,
176 products [38]. Fifteen drugs accounted for just over
half (52 %) of local production in 2005 [37]. Of these
eight were listed on the national essential medicines list
and included amoxicillin (the highest selling drug), cip-
rofloxacin, iron preparations, paracetamol and metro-
nidazole. The public manufacturer, Royal Drugs, focuses
on medicines for public health programmes while the
private producers engage mainly in brand competition
in the private market [39].
The DDA is located in Kathmandu, and aims to “make
available safe, efficacious and quality drug to the general
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public by controlling the production, marketing, distri-
bution, sale, export–import, storage and use of drugs”
through the selection of essential medicines and support
of pharmaceutical industries to comply with WHO-
GMP and to “achieve self-reliance in the production of
essential drugs” [40]. (For a comprehensive overview of
regulations in place see [41].)
Methods
This paper uses a broadly ethnographic approach com-
bining interviews, observations and a review of inter-
national and national literature collected within a
broader research project ‘Tracing pharmaceuticals in
South Asia’ [42]. In Nepal, from 2006 to 2009, the team
undertook more than 170 transcribed semi-structured
interviews, the majority of which were in Nepali and
then translated into English. The interviewees were
people involved in the pharmaceutical production and
distribution chain including producers, medical repre-
sentatives, pharmacists and providers with some having
overlapping roles. Information was collected from four
further categories: international donors, activists, regula-
tors and scientists. The topics were based on an inter-
view schedule and included the everyday working
practices of the interviewees, with particular focus on
the three main drugs of the research (rifampicin, fluoxet-
ine, and oxytocin) and reflecting the broader issues of
regulation, production, access to and rational use of
medicines. In line with the iterative and reflexive qualita-
tive research methodology, topics discussed reflected the
empirical concerns and issues that emerged from the re-
search. In addition extensive participant observation
was conducted in a number of areas in and around
Kathmandu, and in Western Nepal (in clinics, pharma-
cies, OPDs, with Medical Representatives on their
rounds, and visits to two production plants.
Regulatory and policy documents were collected from
the interviewees and from the websites of the Nepal
medicine regulatory agency, WHO and donors.
Ethical review for the project ‘Tracing pharmaceuticals
in South Asia’ as a whole was obtained from the School of
Social and Political Science at the University of Edinburgh,
and for the Nepali element from the Nepal Health
Research Council (NHRC).
Results
Issues with GMP implementation in Nepal
a) Rules are subject to local discretion and regulatory
capacity and not updated in line with WHO
standards
The rules and standards themselves are subject to a
great deal of local discretion and interpretation and this
in itself depends on the role of the enforcers and the
staff who are employed.
Senior DDA officials told us they have developed regu-
lations in the following areas: Drug registration regula-
tions, Drug standard regulations, Drug Inquiry and
Inspection Regulation and Drug manufacturing code.
Drug manufacturing code of 1984 is written in Nepali
and published along with the WHO GMP code of prac-
tice (in English). Despite the WHO revising their GMP
codes in 1998 and 2003, this part has not been updated
in the DDA’s publication. We were told by a senior drug
administrator that the DDA is in the process of publish-
ing a new code as the 1984 DDA code does not explain
certain things clearly; for example, it is written in the
code that “fresh air” is necessary while producing drugs
but it does not explain what is meant by this. When
asked about overlap between the DDA code and WHO
GMP code, he replied in vague terms, saying that most
of the WHO GMP standards are incorporated in the
DDA code (Interview, Senior Drug Administrator, DDA,
June 2007).
From the 1990s the DDA made the upgrading of facil-
ities to WHO GMP standards mandatory. The deadline
was set for April 2007, but by the end of the data collec-
tion period in 2008 only eight companies had managed
this. The then director of the DDA described that the
WHO GMP certification for Nepali companies remained
“optional”, with the DDA’s own Code on Manufacturing
of Drugs the only legally binding requirement. As of
2013 26 of the 58 Nepali companies were compliant
with the WHO GMP (personal communication, 2013).
GMP certification was described by the DDA as neces-
sary only for export [43], although the WHO does inspect
for drugs and products linked to their “own purposes” (for
example vaccination programmes, TB drugs for DOTS,
and ARVs). The WHO role is mainly indirect, through the
DDA. While the Association of Pharmaceutical Producers
of Nepal (APPON) are supposed to be assisting with this
process, and doing trainings around GMP they are
deemed by many to be of little help (as one company dir-
ector stated: “they take our money and drink whisky”!).
During the fieldwork period, they had a volunteer pharma-
cist from Japan helping them with this process of develop-
ing guidelines and trainings. APPON was more involved
in lobbying for dollar rates for imports from India and for
non-tariff barriers such as labelling of all foreign imports
in Nepali.
b) GMP training and capacity
The Director of the DDA described the GMP certifica-
tion process as part of the Essential Drugs and Medi-
cines Programme. The DDA conducted the initial
training in country, with support from the WHO which
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is “technical and financial”. However, the difficulties they
face in implementing the GMP process were described
to us as three fold. Firstly, regulatory capacity relating to
the staff issues and their lack of expertise; this is not
only DDA staffing problems (they had only five staff
members who checked that rules were being followed),
but the lack of expertise in the company staff. While
there are increasing numbers of graduates now coming
out of the universities, to date they have little experi-
ence. Pharmacy is a relatively new discipline in Nepal
(Kathmandu University started their Pharmacist training
course in 1994; the Institute of Medicine set up their
School of Pharmaceutical and Biomedical Sciences in
1997; Pokhara University started in 2000; and Purban-
chal University in 2005). By March 2014 there were
1400 pharmacy graduates registered with Nepal Phar-
macy Council (personal communication) while the DDA
register, in addition to the existing quality control la-
boratories and producers, reported 1688 wholesalers and
8800 retailers of allopathic medicines [44].
Secondly there are difficulties with understanding the
concept. Some manufacturers say that they already sell
well, so why do they need GMP? They have a “market
perspective”, and as their drugs pass their own tests,
why do they need it? They complain about the invest-
ments required for upgrading when they see little bene-
fit. Thirdly, the GMP concepts themselves are changing
and becoming more stringent.
c) Regulatory requirements and associated costs
An interview with a senior member of the of the qual-
ity control division of Nepal Drug Limited, the state run
pharmaceutical company, which was struggling to re-
main in competition with the new private companies, re-
veals the issues they face with GMP (Interview notes,
May 2007). He stated that they did not have the infra-
structure to fulfil GMP standards; that the laboratory
was not well equipped; there was not enough physical
space; human resources were inadequate; there was no
R&D budget; little administrative support; and that the
location of the factory was wrong, due to the poor air
quality in Kathmandu.
“If we have to go to GMP, we need the budget to
improve some of the existing facilities, update them,
and establish a new department to fulfil the
requirement of WHO-GMP…. We have been discuss-
ing to hire consultants from outside to do feasibility
study for focusing on IV Fluid (saline) WHO-GMP
certificate”.
One group of senior management workers for one of
the GMP certified companies described the sheer
production of paperwork required for monitoring as
overwhelming, besides the prohibitive costs. In addition,
the director of one of Nepal’s largest pharmaceutical
companies said that initially their production dropped
after implementing GMP standards. They used to have
“quality control”, but now this has shifted to “quality as-
surance” with greater stringency. This shift was de-
scribed to us by another company’s senior manager as
follows:
“Quality control is not in common use now. We call
it quality assurance. Before while checking quality,
they used to check at the end. But now they say that if
we check it right from the beginning then quality is
assured right from the beginning. The quality of
excipient, whether the raw material is mixed properly
or not, whether it is weighed properly or not, coating,
punching, if everything is done properly, all this is
checked. This is called SOP (Standard Operating
Procedure)” (Interview, Kathmandu, April 2007).
One of the larger more established pharmaceutical
companies had recently upgraded to GMP certification
standards. The director of the company told us that the
initial cost outlay had been 4 crore rupees (That is 40
million rupees, or a little over £300,000 at 2007 ex-
change rates). This had spun them from a profit making
business into one with large debts. An ex-employee of
Royal Drugs Nepal, stated that there was no way that
this company could afford to upgrade to GMP stan-
dards. One particular complaint was that despite this
initial outlay, the Nepal market was small and it would
be difficult to recoup costs (the size of the Nepal market
is stated to us a particular difficulty for Nepal to develop
its own injectables; the market is just too small). Not
one person we interviewed in the business thought of
export as a possibility, and all were concentrating on the
Nepal market.
A senior pharmacology professor referred to the prob-
lem in Nepal as one of quality versus cost. He referred
to amoxicillin, which is now produced by nearly all the
Nepali companies. It costs around 4–5 rupees, but if you
find it for less than this then in his opinion the quality
must be compromised. He reckoned that the then dir-
ector at the DDA was good at his job, and working hard
at trying to keep prices low while maintaining quality; he
was working at trying to get GMP certification imple-
mented. It was difficult, he said, as smaller companies
used to send “goondas” around to him to ask why GMP
was being put into place, claiming that it was driving up
their costs and the prices of affordable medicines.
We were further told that the concepts themselves
have changed a lot. An employee at one company ex-
plained to us how they had shifted to the AHU (air
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handling units) which are stricter, and of the use of “re-
verse osmosis” having replaced “demineralisers” for the
water they use. The costs to run these new units had
increased as well, and the size of the backup generators
required to keep manufacturing standards up with the
regular power cuts have increased. This was a particu-
lar problem in Kathmandu where during the time of
the research power cuts of up to sixteen hours a day
were frequent.
The GMP process was described to us by senior staff
at one company where we were shown around the pro-
duction site, and they bemoaned the sheer volume of re-
cording necessary at every level of production. GMP
certification considers many elements: the premises;
personnel; quality control; production; sanitation and
hygiene and finally, documentation. As they phrased it
all the GMP process “should be done per documentation
and documented”. Each and every activity is prescribed
in detail through Standard Operating Procedures (SOPs),
which are strategically displayed in Nepali and English
throughout the site. The DDA was described as respon-
sible for the guidelines that are set up for this end, and
then responsible for their implantation (Interview,
Kathmandu, April 2007).
d) Impact on local industry and market
Less than half of currently operating companies
achieved the WHO-GMP certification, perhaps due to
the rise in costs. Stricter measures taken in the case of
imported products have resulted in some Indian com-
panies being unable to import their products, and their
products not being re-registered by the DDA (Interview,
wholesaler, April 2007). The producer of “strepsils”
(BOOTS) entered into a contract with a Nepali company
to make this in Nepal, but because the company does
not have GMP certification Strepsils are no longer avail-
able on the Nepal market.
Aid conditionalities and GMP
Although health expenditure from the general govern-
ment has been steadily increasing the foreign aid re-
mains a significant source of health care financing in
Nepal (19 % of total health expenditure in 2008/09). The
dependence is more pronounced in certain areas such as
safe motherhood, immunisation, family health and plan-
ning, TB and leprosy control and STDs [45].
Government regulation currently states that any ten-
der for the government procurement of drugs must be
accompanied by the appropriate paperwork, which in-
cludes GMP certification. Despite the old state run
Nepal Drugs (ND) not having GMP certification, con-
tracts for public procurement are awarded as a priority
to ND.
In the 1990’s ND was formulating rifampicin and sup-
plying the National Tuberculosis Programme with about
1.1 million capsules annually (Interview, ND, February
2007). This was prior to the development of the WHO
prequalification and the GDF), through which Nepal and
other developing countries are currently supplied anti-
TB drugs paid for by the Global Fund and other donors.
After several years ND lost the contract and although it
was not possible to ascertain the key reasons it was sug-
gested that change in management and bribery caused
the loss of contract (Interview, ND, February 2007). In
addition, donors and conditions for international pro-
curement of medicines changed. Currently, even with
the capacity, ND would not be able to supply rifampicin
to the national programme without WHO prequalifica-
tion or other international GMP certificate.
During an interview with a senior advisor to the
Ministry of Health and Population, we were told that
the J-Vaccine (for Japanese Encephalitis) for Nepal was
paid for by Japan and procured by the Nepal govern-
ment from a company in China. The Chinese company
was not GMP certified but the Japan government was
happy with the quality and willing to give money. In
2007 the money for the vaccine was no longer given
directly to Nepal but to UNICEF. Since the WHO, and
other UN agencies, cannot procure any drugs without
GMP certification the Chinese company, which had not
applied for GMP by then, could not supply the product.
In 2005 MoHP launched a zinc programme in the
public health sector procuring zinc from Nutriset in
France. Local producers were also interested in supplying
zinc. The POUNZ project introducing the zinc programme
in the private sector assisted three local manufacturers
with achieving the GMP audit and the three producers
started supplying zinc in 2009. This would not be possible
without the government commitment to this large scale
programme and technical assistance offered by POUNZ.
MoHP is planning to change procurement to the local sup-
pliers who continued working with US Pharmacopeia rep-
resentatives towards WHO prequalification with the view
of reaching to international markets [46, 47]. As of May
2015 no Nepali manufacturer has achieved WHO prequali-
fication [34].
These examples show some of the issues that arise
from GMP certification in a heavily aid dependent state
like Nepal.
Getting around registration: drugs and therapeutics
committees?
Some (private) hospitals have established Drugs and
Therapeutics Committees (DTCs) to get around market
registration. One private hospital director explained that
their committee – established in February 2006 - allows
them to procure from any part of the world, even if that
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drug is not licensed in Nepal with the DDA. He explained
that the DTC formation has been encouraged by the DDA
who “don’t have physicians”, although the government
says what the makeup of the committee should be. The
DTC then can “import” medicines not registered, for ex-
ample important drugs for their hospital cardiac medi-
cines (the hospital specialised initially in cardiology – and
has expanded from that). They have to produce “docu-
ments” – studies and outcomes from these drugs. Thus
they are able to provide data for later registration.
A communication in the Kathmandu University Med-
ical Journal suggested that these committees have a sup-
portive function for the DDA:
“In developing countries like Nepal, where the
pharmacovigilance programs are in its primitive stage,
the DTC has immense responsibility in ensuring drug
safety. This committee can also act as an advisory
committee to the policy makers and drug regulatory
authority of Nepal for drug safety matters based on
their experiences” [48].
GMP and export
By 2012 no Nepali company had yet exported any
pharmaceutical product [38]. However, GMP certifica-
tion is also required for Ayurvedic products. Shakya doc-
uments the experience of a Nepali Ayurvedic company
(Gorkha Ayurved Co.) with exporting medicinal herbs.
The company had no idea that GMP certification was
necessary (or that buyers could also ask for other inter-
nationally harmonised standard of Sanitary and Phyto-
sanitary Measures (SPS). When the company set about
the process of heading towards GMP certification, they
found the RDRL (and the Department for Food Tech-
nology and Quality Control) “without any plan of policy
regarding SPS standards, including GMP certification
procedures”, particularly for Ayurvedic products [49].
Shakya is critical that the DDA had not prepared itself
for accreditation processes, nor determined the basic
mechanisms that companies should take. Businesses
were pretty much on their own, suggested the author,
with the company having huge outlays, including hiring
a foreign expert to assist in the process.
It seems apparent that one consequence of attempting
to harmonise its regulatory capacity will be a greater de-
pendence on foreign assistance (both technical and fi-
nancial) for this process.
Discussion
Our research highlights several issues with implementa-
tion of international GMP standards in a country like
Nepal and how international standards linked to foreign
aid determine production rights of generic medicines
where governments are dependent on aid. Domestic
producers report that compliance with the stringent stan-
dards of GMP is a major obstacle for domestic production
of affordable pharmaceutical products. The lenient ap-
proach to the enforcement of the GMP rules by the Nepali
drug regulator, however, allows the growth of the industry
which remains poorly regulated. These findings are rela-
tively undocumented and unexplored in the literature.
The literature and our interviews highlight the issue of
regulatory capacity building and the interpretation of
standards by inspectors. International institutions and
development agencies offer technical assistance to devel-
oping countries in the form of teaching GMP linked to
capacity building [24, 50] yet, interviewees were con-
cerned that since adherence to GMP standards is subject
to individual experience and interpretation, inspectors
from developed countries may impose more stringent
rules than intended by regulators in developing coun-
tries (interviews with producers in India, [2]).
Our Nepali case study documents problems with GMP
implementation and enforcement due to low regulatory
capacity, insufficient training of staff in the pharmaceut-
ical industry as well as financial constraints. Nepali pro-
ducers do not produce APIs and target only the
domestic market and to that extent they are not directly
affected by internationally harmonised GMP require-
ments, but this also limits their market and their ability
to recoup costs of investment in GMP related upgrades
of manufacturing facilities. Nepali health programmes
funded by international aid largely bypass government reg-
ulators and local producers as international agencies pro-
cure through large companies with an international GMP
certificate. This impacts on local production through re-
duced economies of scale for some classes of medicines as
Nepali companies do not have access to this part of the do-
mestic market. This perhaps also explains the limited focus
of the local industry on essential medicines.
Importance of local production capacity for the supply
of essential medicines and availability of safe, efficacious
and high quality medicines is high on the DDA’s agenda
but there are few incentives for local manufacturers to
produce essential medicines and the relatively long tran-
sition period before the compliance with WHO-GMP
standards is mandatory challenges the acceptance of the
stricter GMP requirements. Producers who already
upgraded their production facilities have to absorb the
cost of GMP compliance (resulting in higher prices of
their products) without gaining recognition of high qual-
ity drug producers (as should be signalled by the GMP
certificate). Some manufacturers question the need for
GMP when their products sell well and there is no evi-
dence to show that the GMP certificate guarantees high
quality and GMP non-compliance results in low quality
end products. It is, however, difficult to determine whether
this is caused by weak enforcement or inadequacy of GMP
Brhlikova et al. Globalization and Health  (2015) 11:25 Page 8 of 10
standards in ensuring high quality of end products. These
conditions are likely to perpetuate the ‘business’ practices
of bonuses, gifts and substitution to push specific products
as opposed to ‘ethical promotion’ [51].
Conclusion
The Nepali local pharmaceutical industry has been
growing significantly over the last decade. Many local
producers are not affected by international quality stan-
dards as they do not export medicines and the DDA
does not enforce the WHO GMP standards strictly. The
evidence suggests that local private manufacturers focus
on brand competition in private consumer markets and
their production of essential medicines is limited to a
few high-volume medicines as the government preferen-
tially procures medicines from the only public producer
and the donor funded health programmes rely on manu-
facturers compliant with international GMP standards.
Further research into access to affordable medicines
via local pharmaceutical production in developing coun-
tries should consider the extent to which international
standards assure quality, safety and efficacy and the cap-
acities of national drug regulatory authorities to enforce
standards where regulators have considerable interpretive
license over standards and their implementation. As things
stand, when aid conditionalities are linked to international
standards the combined effect is to both determine and
confer production rights and thus affect viability of local
pharmaceutical industry and their incentives to produce
essential medicines within low-income countries.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
PB and AMP conceived of the study, PB, AMP and IH drafted the manuscript.
PB carried out literature reviews. IH coordinated data collection in Nepal. IH,
MS, SB, NR participated in the design, data collection and analysis. All
authors read and approved the final manuscript.
Acknowledgements
This work was supported by the Economic and Social Research Council and
the Department for International Development [RES-167-25-0110] through
the collaborative research project Tracing Pharmaceuticals in South Asia
(2006–2009). In addition to the authors of this paper, the project team
included: Soumita Basu, Gitanjali Priti Bhatia, Erin Court, Abhijit Das, Stefan
Ecks, Patricia Jeffery, Roger Jeffery, Rachel Manners, and Liz Richardson.
Martin Chautari (Kathmandu) and the Centre for Health and Social Justice
(New Delhi) provided resources drawn upon in writing this paper but are
not responsible for the views expressed, nor are ESRC or DFID.
Ethical review was provided by the School of Social and Political Science at
the University of Edinburgh, and ethical approval in Nepal for the study
granted by the Nepal Health Research Council (NHRC).
Author details
1Centre for Primary Care and Public Health, Queen Mary University of
London, 58 Turner Street, London E1 2AB, UK. 2School of Social and Political
Science, University of Edinburgh, 15a George Square, Edinburgh EH8 9LD,
UK. 3Patan Academy of Health Sciences, Nepal and Central Department of
Sociology and Anthropology, Tribhuvan University, Kathmandu, Nepal.
4Northeastern University, Boston, MA, USA. 5Central Department of
Sociology/Anthropology, Tribhuvan University, Kathmandu, Nepal.
Received: 6 November 2014 Accepted: 1 June 2015
References
1. WHO. Global strategy and plan of action on public health, innovation and
intellectual property. Geneva: World Health Organization; 2011.
2. Losse K, Schneider E, Spennemann C. The viability of local pharmaceutical
production in Tanzania. Eschborn: Deutsche Gesellschaft für Technische
Zusammenarbeit (GTZ) GmbH; 2007.
3. Chaudhuri S. The WTO and India’s Pharmaceuticals Industry: Patent
Protection, TRIPS, and Developing Countries. New Delhi: Oxford University
Press; 2005.
4. WHO. Local production for access to medical products: developing a
framework to improve public health. Geneva: World Health Organization; 2011.
5. Kaplan W, Laing R. Local production of pharmaceuticals: industrial policy
and access to medicines. An overview of key concepts, issues and
opportunities for future research, in HNP Discussion Paper. Washington: The
World Bank; 2005.
6. UNCTAD. Investment in Pharmaceutical Production in the Least Developed
Countries: A Guide for Policymakers and Investment Promotion Agencies.
Geneva: United Nations; 2011.
7. WHO. World Medicines Situation. Geneva: World Health Organization; 2004.
8. Kaplan WA, Ritz LS, Vitello M. Local production of medical technologies and
its effect on access in low and middle income countries: a systematic
review of the literature. Southern Med Rev. 2011;4(2):51–61.
9. Mujinja PG et al. Local production of pharmaceuticals in Africa and access
to essential medicines: ‘urban bias’ in access to imported medicines in
Tanzania and its policy implications. Glob Health. 2014;10:12.
10. Timmermans K. Harmonization, regulation, and trade: interactions in the
pharmaceutical field. Int J Health Serv. 2004;34(4):651–61.
11. Abraham J, Reed T. Trading risks for markets: the international
harmonization of pharmaceuticals regulation. Health Risks Soc.
2001;3(1):113–28.
12. Grimes DA et al. The Good Clinical Practice guideline: a bronze standard for
clinical research. Lancet. 2005;366(9480):172–4.
13. WHO. The Impact of Implementation of ICH Guidelines in Non-ICH
Countries. In: Regulatory Support Series, No. 9. Geneva: World Health
Organization; 2002.
14. Santhosh M, Singh A. Booklet on Access to Medicines in India. New Delhi:
CLRA-Centad; 2009.
15. WHO. WHO Expert Committee on Specifications for Pharmaceutical
Preparations, in WHO Technical Report Series. 2011.
16. WHO. Guidelines on the implementation of the WHO certification scheme
on the quality of pharmaceutical products moving in international
commerce. 2014 [cited 2014 July 3]; Available from: http://www.who.int/
medicines/areas/quality_safety/regulation_legislation/certification/
guidelines/en/.
17. PIC/S. Pharmaceutical Inspection Co-operation Scheme: Role. 2014 [cited
2014 July 14]; Available from: http://www.picscheme.org.
18. WHO. Annex 2: WHO good manufacturing practices for active
pharmaceutical ingredients in WHO Technical Report Series. Geneva: World
Health Organization; 2010.
19. WHO. Assessment of medicines regulatory systems in 26 sub-Saharan
African countries: An overview of findings from 26 assessment reports.
Geneva: World Health Organization; 2010.
20. GAO. Drug Safety: Better Data Management and More Inspections Are
Needed to Strengthen FDA’s Foreign Drug Inspection Program.
Washington, D.C: United States Government Accountability Office; 2008.
21. Global Fund. 6th Invitation to manufacturers of antimalarial medicines to
submit an Expression of Interest (EoI) for product evaluation by Expert
Review Panel (ERP). 2011.
22. PEPFAR. Fiscal year 2008: PEPFAR operational Plan. 2008.
23. Blake S et al. U.N. Commission on Life Saving Commodities for Women and
Children:Country Case Studies. 2012. [cited 2015 June 7]; Available from:
http://can-mnch.ca/wp-content/uploads/2012/06/Life-Saving-Commodities-
New_Concept_Note1.pdf.
24. Hill S, Johnson K. Emerging challenges and opportunities in drug
registration and regulation in developing countries. London: DFID Health
Systems Resource Centre; 2004.
25. Brhlikova P et al. Trust and the regulation of pharmaceuticals: South Asia in
a globalised world. Glob Health. 2011;7:10.
Brhlikova et al. Globalization and Health  (2015) 11:25 Page 9 of 10
26. Meshkini AH et al. Assessment of the vaccine industry in Iran in context of
accession to WTO: a survey study. DARU J Pharm Sci. 2012;20:19.
27. Pinheiro ES et al. Production of antiretroviral drugs in middle- and
low-income countries. Antivir Ther. 2014;19 Suppl 3:49–55.
28. Abdo-Rabbo A, Bassili A, Atta H. The quality of antimalarials available in
Yemen. Malar J. 2005;4:28.
29. Trouiller P, Folb P, Weerasuriya K. Legal and regulatory issues affecting drug
development for neglected diseases: harmonization of technical
requirements for registration of pharmaceuticals for human use. 2001.
30. Trouiller P et al. The globalisation of regulatory requirements, and the
development and availability of medicinal products in developing countries:
quality, efficacy and safety issues. 2002.
31. UNIDO. Independent evaluation: Strengthening the local production of
essential generic drugs in least developed/developing countries. Vienna:
UNIDO; 2010.
32. Guimier J-M, Lee E, Grupper M. Processes and issues for improving access to
medicines: the evidence base for domestic production and greater access to
medicines. London: DFID Health Systems Resource Centre; 2004.
33. WHO WHO. Prequalification: Building quality-assured manufacturing
capacity in Nigeria. WHO Drug Inf. 2014;28(4):425–30.
34. WHO. WHO List of Prequalified Medicinal Products. 2015 [cited 2015 17
April]; Available from: http://apps.who.int/prequal/query/
ProductRegistry.aspx.
35. WHO. WHO List of Prequalified Active Pharmaceutical Ingredients. 2015
[cited 2015 April 17]; Available from: http://apps.who.int/prequal/
info_applicants/API_PQ-List.htm.
36. Dixit H. Nepal’s Quest for Health. Kathmandu: Educational Books Publishing
(P) Ltd; 2000.
37. SAWTEE. WTO and public health policy priorities for Nepal. Kathmandu:
SAWTEE; 2006.
38. HSSP. Quality assurance of medicines in Nepal: identified needs for capacity
enhancement. Kathmandu: Deutsche Gesellschaft für Internationale
ZusammenarbeitHealth Sector Support Programme; 2012.
39. Budhathoki S. Drug Drive: The Rising Business of Pharmaceutical Companies
in Nepal, in New Business Age. 2012.
40. DDA. Department of Drug Administration: Objectives. 2007.
41. MHP. Nepal Pharmaceutical Country Profile. 2011.
42. Jeffery R. Tracing Pharmaceuticals in South Asia: Project Design and Basic
Data. 2010. [cited 2015 June 7]; Available from: http://www.csas.ed.ac.uk/
__data/assets/pdf_file/0005/49244/
Tracing_Pharmaceuticals_in_South_Asia_WP2010.pdf.
43. Thapa. Editorial: GMP Certification for Assuring the Quality of
Pharmaceutical Products. Drug Bull Nepal. 2004;16(1):3–4.
44. DDA. Regulatory news. Drug Bulletin of Nepal. 2012;24(1)
45. Shrestha B et al. Nepal National Health Accounts, 2006/2007 - 2008/2009.
Kathmandu: Health Economics and Financing Unit, Ministry of Health and
Population, Government of Nepal; 2012.
46. Mosites E, et al. Nepal zinc case study. University of Washington Global
Health START Program; 2012 ect.org/sites/default/files/resources/
Nepal_Zinc%20Case%20Study_0.pdf.
47. Toledo E. USP DQI Good Manufacturing Practices Assessment for
Manufacturers of Zinc Sulfate Tablets and Chlorhexidine Kathmandu, Nepal;
January 14–22, 2008. Rockville, Maryland: United States Pharmacopeia:
Submitted to the U.S. Agency for International Development by the United
States Pharmacopeia Drug Quality and Information Program; 2009.
48. Palaian S, Mishra P. Role of drug and therapeutics committee towards drug
safety–experiences from western Nepal. Kathmandu Univ Med J (KUMJ).
2005;3(1):79–80.
49. Shakya B. Nepal: Exports of Ayurvedic Herbal Remedies and SPS Issues. In:
Gallagher P, Low P, Stoler A, editors. Managing the Challenges of WTO
Participation: 45 Case Studies. Cambridge: Cambridge University Press; 2005.
50. Morimoto K et al. Promoting GMP implementation: developing training
materials for the international audience. Qual Assur. 2003;10(1):11–27.
51. Harper I, Rawal N, Subedi M. Disputing distribution: ethics and
pharmaceutical regulation in Nepal. Studies Nepali Hist Soc. 2011;16(1):1–39.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Brhlikova et al. Globalization and Health  (2015) 11:25 Page 10 of 10
